| Description | MBC-11 A coupling agent that targets cancer by concentrating cytarabine and etidronate at the site of disease.MBC-11 is used to study tumor-induced bone disease. |
| In vitro | 在人多发性骨髓瘤细胞系（KAS-6/1、DP-6、KP-6）中，MBC-11（0.1-100uM）能够显著抑制大多数测试浓度下每个细胞系的多发性骨髓瘤细胞增殖[1]。 |
| In vivo | 在约四周龄的雌性 Balb/c 乳腺肿瘤模型小鼠中，MBC-11（0.04, 0.4, 或 4μg/d；从第 7 天到第 21 天每日皮下注射）在0.04 μg/d的剂量下，相比于 PBS 或0.04 μg/d 唑来膦酸处理组，具有较低的骨转移发生率[1]。 |
| molecular weight | 511.21 |
| Molecular formula | C11H20N3O14P3 |
| CAS | 332863-86-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Reinholz MM, et al. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone. 2010 Jul;47(1):12-22. 2. Zinnen SP, et al. First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease. Oncologist. 2019 Mar;24(3):303-e102. |